Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Biomarin Pharmaceutical Inc (BMRN)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Biomarin Pharma's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
82.44 -1.36    -1.62%
- Closed. Currency in USD ( Disclaimer )
After Hours
81.55
-0.89
-1.08%
- Real-time Data
Type:  Equity
Market:  United States
  • Volume: 1,606,457
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 82.32 - 84.80
Biomarin Pharma 82.44 -1.36 -1.62%

NASDAQ:BMRN Financials

 
A brief overview of the NASDAQ:BMRN financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of BioMarin over time.

BioMarin Pharmaceutical Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was USD 648.83 million compared to USD 596.42 million a year ago. Net income was USD 88.66 million compared to USD 50.85 million a year ago. Basic earnings per share from continuing operations was USD 0.47 compared to USD 0.27 a year ago. Diluted earnings per share from continuing operations was USD 0.46 compared to USD 0.27 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

BMRN Income Statement

Gross margin TTM 49.34%
Operating margin TTM 7.61%
Net Profit margin TTM 8.31%
Return on Investment TTM 2.84%
 Total Revenue  Net Income
Period Ending: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023
Total Revenue 648.83 646.21 581.33 595.28
Gross Profit 318.67 304.48 265.27 289.83
Operating Income 81.86 28.22 25.66 58.87
Net Income 88.66 20.38 40.38 56.04

BMRN Balance Sheet

Quick Ratio MRQ 1.55
Current Ratio MRQ 2.74
LT Debt to Equity MRQ 11.7%
Total Debt to Equity MRQ 21.61%
 Total Assets  Total Liabilities
Period Ending: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023
Total Assets 6872.67 6841.6 6758.16 6563.17
Total Liabilities 1798.86 1890.05 1861.27 1780.34
Total Equity 5073.82 4951.55 4896.9 4782.83

BMRN Cash Flow Statement

Cash Flow/Share TTM 1.48
Revenue/Share TTM 13.1
Operating Cash Flow  4.32%
 Cash  Net Change in Cash
Period Ending: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 46.97 27.48 135.65 70.06
Cash From Investing Activities -14.24 -64.96 -45.8 29.53
Cash From Financing Activities -42.79 10.84 -0.788 11.96
Net Change in Cash -8.13 -30.29 91.03 114.31
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

BMRN Comments

Write your thoughts about Biomarin Pharmaceutical Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Lisa Solomon
Lisa Solomon Aug 24, 2022 12:35PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
h projections of 15% revenue expansion this fiscal year and an additional 30% growth rate projected for fiscal year 2023
Reply
0 0
Report
Mario Conde
Mario Conde Nov 19, 2021 3:38PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
what's going on, why did I finally recover my investment lol. Been off for quite some time.
Reply
2 0
Report
Mario Conde
Mario Conde Nov 19, 2021 3:38PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Ok treatment for dwarfism approved by FDA
Reply
0 0
Report
Financial Advisors
Financial Advisors Nov 19, 2021 3:38PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
WHAT price you you entried since when ? they got FDA approval and the price have not rised up ? can you help me a little to understand? possible i can give you an explanation.! i had same bad experience with ETON.
Reply
0 0
Report
Adebayo Oyebami
Adebayo Oyebami Oct 27, 2021 7:30PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Hi everyone am new comer i want to know more about the investments
Reply
1 0
Report
King David
TheKingDavid Oct 27, 2021 7:30PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
New fish, welcome
Reply
1 0
Report
Ivan Popovic
Ivan Popovic Oct 27, 2021 7:30PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
do you need opinions or advises to earn ?
Reply
0 0
Report
Ivan Popovic
Ivan Popovic Oct 27, 2021 7:30PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
please feel free to ask .
Reply
0 0
Report
Jeff Bailey
JeffB Oct 27, 2021 4:27PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
BMRN $71.72 @ Close! (Earnings)
Reply
0 0
Report
Caldararu narcis
Caldararu narcis Oct 27, 2021 4:21PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
give pls
Reply
0 0
Report
King David
TheKingDavid Jul 22, 2021 3:05PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Almost 5 months sick stock.not growing nowhere.
Reply
3 1
Report
Luke Sky
Luke Sky Apr 24, 2021 1:22PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Give the anti-corona spray from marinomed-biotech some VC and invest in a pharma company which is heading to the moon:https://www.investing.com/equities/marinomed-biotech-agStudies are proving that the patented method of marinomed prevents infection with all Corona varietis including mutants. It also prevents other virus infections. They have many patents.  Do some good and get rich
Reply
2 1
Report
Ali Daher
Ali Daher Mar 26, 2021 9:08AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Biomarin are undervalued. They should be a 100$ stock
Reply
3 0
Report
King David
TheKingDavid Mar 16, 2021 9:40AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
This stock is sick.
Reply
1 1
Report
Manisa Manisa
Manisa Manisa Mar 05, 2021 10:28AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
This stock is very resilient!
Reply
1 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email